Together, these results demonstrate that CS2 counteracts αSyn-induced ClpP deficiency, reduces pathological αSyn accumulation, and restores neuronal, synaptic, and mitochondrial integrity in patient-derived DA neurons, supporting its potential as a disease-modifying therapeutic agent for PD. This evidence concerns the gene CLPP and Parkinson disease.